Hospital Endoscopy Equipment Market

The hospital endoscopy equipment market is worth USD 13,630.0 million in 2025 and reaches USD 27,077.4 million by 2035, compounding at 7.11% a year. The figure is built bottom-up: roughly 235 million endoscopic procedures performed in 2025 across gastrointestinal, pulmonary, urological, gynaecological and surgical specialties, at an average equipment spend of USD 58 per procedure covering flexible video endoscopes, visualization systems, processors and light sources, rigid endoscopes and surgical visualization, and single use endoscopes and artificial intelligence detection software, triangulated against procedure volumes, installed bases and manufacturer disclosures. Procedures grow 4.8% a year as screening expands and ageing populations need more diagnosis, while equipment spend per procedure rises 2.2% a year as single use scopes, higher definition imaging and artificial intelligence raise content. This study sits within our diagnostic devices coverage and follows the published Douglas Insights methodology.

Why did infections push the market toward single use scopes?

Because some reusable endoscopes proved almost impossible to clean reliably, and outbreaks of drug resistant infections traced to them forced regulators and hospitals to rethink the model. Flexible endoscopes are long, narrow, complex instruments with internal channels and moving parts, and they are reprocessed between patients through cleaning and high level disinfection rather than full sterilisation. Duodenoscopes, used to access the bile and pancreatic ducts, have a particularly intricate tip mechanism, and in the 2010s several hospitals experienced outbreaks of antibiotic resistant bacteria transmitted between patients through contaminated duodenoscopes despite reprocessing that followed manufacturer instructions. Regulators responded by requiring design changes and recommending that hospitals transition to duodenoscopes with disposable components or fully single use designs. That opened a market for single use endoscopes, which eliminate reprocessing and cross contamination risk and have since spread to bronchoscopes, urological scopes and other types, particularly where reprocessing is costly or infection risk high. Single use scopes carry per procedure costs that shift spending from capital to consumables. The exclusive chapter of this report compares the cost per procedure of reusable and single use scopes by type, since that comparison drives adoption.

What does this market include?

This study covers equipment used to perform endoscopic procedures in hospitals and ambulatory centres. Flexible video endoscopes cover reusable gastroscopes, colonoscopes, duodenoscopes, bronchoscopes, ureteroscopes and other flexible scopes. Visualization systems, processors and light sources cover the video processors, monitors, light sources and image management systems that endoscopes connect to. Rigid endoscopes and surgical visualization cover rigid scopes and camera systems used in laparoscopic, arthroscopic and other minimally invasive surgery. Single use endoscopes and artificial intelligence detection software cover disposable endoscopes and software that assists detection of lesions such as colorectal polyps. Endoscopic accessories and consumables such as biopsy forceps, snares and balloons covered in our separate biopsy and catheter coverage, endoscope reprocessing equipment covered in our sterile processing coverage, and surgical robots sit outside the boundary. Value is measured at the price facilities pay.

What is artificial intelligence changing in endoscopy?

It is helping endoscopists see what they would otherwise miss, which in colorectal screening has direct consequences for cancer prevention. During colonoscopy, the endoscopist looks for polyps, some of which can develop into cancer, and removes them, but studies show that a meaningful share of polyps are missed, particularly small or flat ones, and miss rates vary widely between endoscopists. Computer aided detection systems analyse the video feed in real time and highlight suspected polyps on the screen, and clinical studies have shown they increase the rate at which polyps and adenomas are detected. Regulators have cleared such systems, and they are being adopted in screening programmes. Artificial intelligence is also being applied to characterise lesions, assess the quality of examinations, and support other endoscopic procedures. For this market, artificial intelligence adds software value to endoscopy systems and encourages upgrades to compatible platforms, and it supports the case for high quality screening. Its effect on procedure volume may be modest, but its effect on outcomes and on the value of equipment is growing.

What drives demand?

The first driver is cancer screening. Colorectal cancer screening programmes, including lower starting ages in some countries, and growing screening for gastric and lung cancers increase endoscopic procedure volumes.

The second driver is ageing populations. Older people require more diagnostic and therapeutic endoscopy for gastrointestinal, pulmonary and urological conditions.

The third driver is minimally invasive surgery. The continued shift from open to minimally invasive surgery drives demand for rigid endoscopes and surgical visualization.

The fourth driver is infection prevention. Concern about cross contamination drives adoption of single use scopes and better reprocessing, supporting spending.

What restrains the market?

Three restraints are modelled. Capital budgets are the first: endoscopy systems and scope fleets are significant capital purchases that compete with other hospital priorities, and replacement can be deferred. Single use cost and sustainability are second: single use scopes raise per procedure costs and create medical waste, and debate about their environmental impact and cost effectiveness limits adoption in some settings. Market concentration and quality issues are third: a small number of manufacturers dominate flexible endoscopy, and regulatory actions over quality at a leading manufacturer have caused supply and compliance concerns, affecting hospitals’ procurement.

Which equipment categories carry the value?

Flexible video endoscopes lead with 38% of 2025 value, USD 5,179.4 million, the core of gastrointestinal and pulmonary endoscopy, with large replacement demand. Visualization systems, processors and light sources hold 24%, USD 3,271.2 million, upgraded periodically to higher definition and enhanced imaging. Rigid endoscopes and surgical visualization account for 22%, USD 2,998.6 million, driven by minimally invasive surgery. Single use endoscopes and artificial intelligence detection software contribute 16%, USD 2,180.8 million, and grow fastest as single use scopes spread and artificial intelligence is adopted. Each category is modelled through 2035 by specialty and region.

Where is endoscopy equipment used?

North America leads with 38% of 2025 value, USD 5,179.4 million, growing 6.4% a year, reflecting high procedure volumes, colorectal screening from a younger age, and early adoption of single use scopes and artificial intelligence. Asia Pacific holds 28%, USD 3,816.4 million, and grows fastest at 8.5%, driven by high gastric cancer screening in Japan and South Korea, rapid growth of endoscopy in China and expanding access in India and Southeast Asia. Europe holds 26%, USD 3,543.8 million, at 6.2%, with established screening programmes. Latin America contributes USD 545.2 million at 7.8%, the Middle East USD 408.9 million at 8.4% and Africa USD 136.3 million at 7.6%. Six regional models sum to the global figure, with country tables in the Excel model.

Who supplies endoscopy equipment?

Olympus is the dominant supplier of flexible endoscopes worldwide, particularly in gastrointestinal endoscopy, though regulatory actions concerning quality at some of its facilities have created compliance challenges. Fujifilm and Pentax Medical, part of Hoya, are the other major flexible endoscope manufacturers. Karl Storz, Stryker, Richard Wolf and Olympus supply rigid endoscopes and surgical visualization. Ambu is a leading supplier of single use endoscopes, and Boston Scientific supplies single use duodenoscopes and ureteroscopes. Medtronic and others supply artificial intelligence detection systems. Chinese manufacturers including Sonoscape and Aohua have grown in their domestic market and are expanding abroad. The competitive chapter profiles each supplier’s product range, installed base, single use and artificial intelligence position and regional presence.

How is endoscopy equipment priced?

Average equipment spend is USD 58 per procedure in 2025, reflecting the amortised cost of scopes and systems across many procedures plus single use scope costs where used. A reusable flexible endoscope costs tens of thousands of dollars and is used for many procedures, with repair costs significant over its life, while a video processor and tower cost more. Single use endoscopes cost from several hundred to over a thousand dollars each depending on type, a large per procedure cost compared with reusable scopes but avoiding reprocessing and repair. Artificial intelligence software is sold as licences or subscriptions. Manufacturers frequently offer fleet agreements covering scopes, systems, repair and service over several years. The pricing chapter publishes price bands by equipment type and the per procedure cost of reusable and single use scopes.

How do the scenarios diverge by 2035?

The base case carries 4.8% growth in procedures and 2.2% growth in equipment spend per procedure for a 7.11% revenue CAGR and USD 27,077.4 million in 2035. The constrained-budget scenario, in which hospital capital is tight and single use adoption stalls on cost and sustainability, sets the legs at 3.2% and 1.0%, landing near USD 20,180 million. The screening-expansion scenario, in which screening widens, single use scopes spread and artificial intelligence is standard, sets them at 6.0% and 3.4%, carrying the market past USD 33,800 million. Each 1-point change in procedure growth moves the 2035 figure by roughly USD 2,480 million.

Which rules and standards apply?

Three layers matter. Medical device regulation comes first: endoscopes, visualization systems and artificial intelligence software are regulated medical devices requiring clearance, and regulators have required design changes and additional testing for endoscopes linked to infection risk. Reprocessing standards and guidance are second: standards and regulatory guidance for cleaning and disinfecting reusable endoscopes, and requirements for validated reprocessing instructions, affect the cost and risk of reusable scopes and support the case for single use designs. Cancer screening guidelines are third: national screening guidelines, including recommended starting ages and intervals for colorectal screening, drive procedure volumes. The regulatory chapter maps these requirements by jurisdiction.

Is single use the future of endoscopy?

For certain scope types, largely yes, but reusable scopes are likely to remain dominant overall within this forecast period, and the balance depends on cost, infection risk and sustainability. Single use scopes make the strongest case where infection risk is high, reprocessing is difficult or expensive, and procedure volumes are low or unpredictable: bronchoscopes in intensive care units, where urgent procedures happen around the clock and reprocessing capacity is limited; duodenoscopes, where contamination has been a documented problem; and ureteroscopes, which suffer frequent costly damage. In high volume gastrointestinal endoscopy such as colonoscopy, where reusable scopes are used many times a day and reprocessing is well established, reusable scopes generally remain more economical, and the waste generated by single use scopes raises environmental concerns that hospitals increasingly weigh. The likely outcome is a mixed model, with single use scopes gaining a substantial share in specific applications and reusable scopes remaining the norm for high volume procedures. The model reflects single use growth concentrated in these applications.

Douglas Exclusive: the reusable versus single use cost model

This report models, by scope type and facility, the total cost per procedure of reusable scopes including purchase, reprocessing, repair and infection risk, against single use scopes including purchase and waste disposal, identifying where each is more economical and converting procedure forecasts into equipment demand by category and region. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The model is built bottom-up from procedures: endoscopic procedure volumes by specialty and region, installed scope and system bases, replacement cycles, single use and artificial intelligence adoption, and realised prices from manufacturer disclosures, with endoscopic accessories, reprocessing equipment and surgical robots excluded. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.